Cell kinetics in ovarian cancer. Relationship to clinicopathologic features, responsiveness to chemotherapy, and survival

P. F. Conte, A. Alama, A. Rubagotti, S. Chiara, A. Nicolin, G. Nicolo, R. Rosso, M. Gaddi, B. Ghiringhello, S. Tomao, G. Foglia, N. Ragni

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The tumor proliferative activity of 74 previously untreated epithelial ovarian carcinomas was evaluated by the thymidine labeling index (TLI) and the primer-dependent alpha DNA polymerase assay (PDP-LI). The median TLI and PDP-LI were 2% (0.1 to 28.0) and 10% (3.0 to 80.0%), respectively. The TLI was significantly correlated to tumor grade, International Federation of Gynecology and Obstetrics (FIGO) stage, and residual disease. However, neither the TLI nor the PDP-LI was a predictor of survival. A higher response rate was observed in the case of rapidly proliferating tumors: an objective response (OR) was observed in 38.4% of the patients with a low TLI and in 53.6% of the patients with a high TLI. The advantage of an OR in favor of the high TLI group was significant for patients treated with regimens containing doxorubicin (high TLI, 72.2% OR; low TLI, 40% OR; P = 0.03).

Original languageEnglish
Pages (from-to)1188-1191
Number of pages4
JournalCancer
Volume64
Issue number6
Publication statusPublished - 1989

Fingerprint

Ovarian Neoplasms
Thymidine
Drug Therapy
Survival
Neoplasms
DNA Polymerase I
Gynecology
Doxorubicin
Obstetrics
Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cell kinetics in ovarian cancer. Relationship to clinicopathologic features, responsiveness to chemotherapy, and survival. / Conte, P. F.; Alama, A.; Rubagotti, A.; Chiara, S.; Nicolin, A.; Nicolo, G.; Rosso, R.; Gaddi, M.; Ghiringhello, B.; Tomao, S.; Foglia, G.; Ragni, N.

In: Cancer, Vol. 64, No. 6, 1989, p. 1188-1191.

Research output: Contribution to journalArticle

Conte, PF, Alama, A, Rubagotti, A, Chiara, S, Nicolin, A, Nicolo, G, Rosso, R, Gaddi, M, Ghiringhello, B, Tomao, S, Foglia, G & Ragni, N 1989, 'Cell kinetics in ovarian cancer. Relationship to clinicopathologic features, responsiveness to chemotherapy, and survival', Cancer, vol. 64, no. 6, pp. 1188-1191.
Conte, P. F. ; Alama, A. ; Rubagotti, A. ; Chiara, S. ; Nicolin, A. ; Nicolo, G. ; Rosso, R. ; Gaddi, M. ; Ghiringhello, B. ; Tomao, S. ; Foglia, G. ; Ragni, N. / Cell kinetics in ovarian cancer. Relationship to clinicopathologic features, responsiveness to chemotherapy, and survival. In: Cancer. 1989 ; Vol. 64, No. 6. pp. 1188-1191.
@article{b065c508beef43598b0d93e437a2beaa,
title = "Cell kinetics in ovarian cancer. Relationship to clinicopathologic features, responsiveness to chemotherapy, and survival",
abstract = "The tumor proliferative activity of 74 previously untreated epithelial ovarian carcinomas was evaluated by the thymidine labeling index (TLI) and the primer-dependent alpha DNA polymerase assay (PDP-LI). The median TLI and PDP-LI were 2{\%} (0.1 to 28.0) and 10{\%} (3.0 to 80.0{\%}), respectively. The TLI was significantly correlated to tumor grade, International Federation of Gynecology and Obstetrics (FIGO) stage, and residual disease. However, neither the TLI nor the PDP-LI was a predictor of survival. A higher response rate was observed in the case of rapidly proliferating tumors: an objective response (OR) was observed in 38.4{\%} of the patients with a low TLI and in 53.6{\%} of the patients with a high TLI. The advantage of an OR in favor of the high TLI group was significant for patients treated with regimens containing doxorubicin (high TLI, 72.2{\%} OR; low TLI, 40{\%} OR; P = 0.03).",
author = "Conte, {P. F.} and A. Alama and A. Rubagotti and S. Chiara and A. Nicolin and G. Nicolo and R. Rosso and M. Gaddi and B. Ghiringhello and S. Tomao and G. Foglia and N. Ragni",
year = "1989",
language = "English",
volume = "64",
pages = "1188--1191",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Cell kinetics in ovarian cancer. Relationship to clinicopathologic features, responsiveness to chemotherapy, and survival

AU - Conte, P. F.

AU - Alama, A.

AU - Rubagotti, A.

AU - Chiara, S.

AU - Nicolin, A.

AU - Nicolo, G.

AU - Rosso, R.

AU - Gaddi, M.

AU - Ghiringhello, B.

AU - Tomao, S.

AU - Foglia, G.

AU - Ragni, N.

PY - 1989

Y1 - 1989

N2 - The tumor proliferative activity of 74 previously untreated epithelial ovarian carcinomas was evaluated by the thymidine labeling index (TLI) and the primer-dependent alpha DNA polymerase assay (PDP-LI). The median TLI and PDP-LI were 2% (0.1 to 28.0) and 10% (3.0 to 80.0%), respectively. The TLI was significantly correlated to tumor grade, International Federation of Gynecology and Obstetrics (FIGO) stage, and residual disease. However, neither the TLI nor the PDP-LI was a predictor of survival. A higher response rate was observed in the case of rapidly proliferating tumors: an objective response (OR) was observed in 38.4% of the patients with a low TLI and in 53.6% of the patients with a high TLI. The advantage of an OR in favor of the high TLI group was significant for patients treated with regimens containing doxorubicin (high TLI, 72.2% OR; low TLI, 40% OR; P = 0.03).

AB - The tumor proliferative activity of 74 previously untreated epithelial ovarian carcinomas was evaluated by the thymidine labeling index (TLI) and the primer-dependent alpha DNA polymerase assay (PDP-LI). The median TLI and PDP-LI were 2% (0.1 to 28.0) and 10% (3.0 to 80.0%), respectively. The TLI was significantly correlated to tumor grade, International Federation of Gynecology and Obstetrics (FIGO) stage, and residual disease. However, neither the TLI nor the PDP-LI was a predictor of survival. A higher response rate was observed in the case of rapidly proliferating tumors: an objective response (OR) was observed in 38.4% of the patients with a low TLI and in 53.6% of the patients with a high TLI. The advantage of an OR in favor of the high TLI group was significant for patients treated with regimens containing doxorubicin (high TLI, 72.2% OR; low TLI, 40% OR; P = 0.03).

UR - http://www.scopus.com/inward/record.url?scp=0024434114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024434114&partnerID=8YFLogxK

M3 - Article

C2 - 2766216

AN - SCOPUS:0024434114

VL - 64

SP - 1188

EP - 1191

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -